The SCN9A Polyclonal Antibody (PAC020406) is a crucial tool for researchers studying the SCN9A gene, which encodes for the Nav1.7 sodium channel involved in pain sensation. This antibody, produced in rabbits, exhibits high specificity and sensitivity in detecting SCN9A in human samples, making it an ideal choice for Western blot applications. By binding to the SCN9A protein, researchers can accurately analyze its expression and function in various cell types.The Nav1.7 sodium channel, encoded by the SCN9A gene, plays a pivotal role in pain perception and transmission in the nervous system. Dysregulation of this channel has been linked to various pain disorders, making it a promising target for therapeutic interventions.
Research on SCN9A could potentially lead to the development of novel treatments for chronic pain conditions, such as neuropathic pain and certain neurological disorders.The SCN9A Polyclonal Antibody is a valuable tool for scientists investigating the molecular mechanisms underlying pain processing and exploring potential therapeutic strategies targeting the Nav1.7 channel. With its high quality and reliability, this antibody is essential for advancing our understanding of pain biology and developing innovative treatments for pain-related conditions.
Antibody Name:
SCN9A Antibody (PACO20406)
Antibody SKU:
PACO20406
Size:
50ul
Host Species:
Rabbit
Tested Applications:
ELISA, IHC
Recommended Dilutions:
ELISA:1:1000-1:2000, IHC:1:10-1:50
Species Reactivity:
Human
Immunogen:
Synthetic peptide of human SCN9A
Form:
Liquid
Storage Buffer:
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Purification Method:
Antigen affinity purification
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20406(SCN9A Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: x200).
Background:
This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder.
